VXLLF (Vaxil Bio) Stock Based Compensation: $0.00 Mil (TTM As of Mar. 2026)


VXLLF Vaxil Bio Ltd VXLLF
36 GF Score
Price $0.04
! 2 Warning Signs
View Full Analysis

What is Vaxil Bio Stock Based Compensation?

Vaxil Bio VXLLF 36 Stock Based Compensation is $0.00 Mil as of Mar. 2026. GuruFocus rates VXLLF with a GF Score™ of 36/100. The stock has 2 warning signs investors should review.

Vaxil Bio's Stock Based Compensation for the three months ended in Mar. 2026 was $0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Vaxil Bio Stock Based Compensation Related Terms

Vaxil Bio Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Vaxil Bio's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaxil Bio Stock Based Compensation Chart

Vaxil Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 0.01 0.02 0.00 0.00

Vaxil Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
VXLLF
36GF Score
Vaxil Bio Ltd VXLLF
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vaxil Bio Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

What does a Stock Based Compensation of $0.00 Mil mean?
Vaxil Bio (VXLLF) has a Stock Based Compensation of $0.00 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Vaxil Bio and its competitors.
Is Vaxil Bio's Stock Based Compensation too high?
Vaxil Bio's current Stock Based Compensation is $0.00 Mil. Overall, Vaxil Bio has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Vaxil Bio's Stock Based Compensation compare to VRTX and REGN?
Vaxil Bio's Stock Based Compensation of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Vaxil Bio and its competitors. Vaxil Bio's current Stock Based Compensation is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaxil Bio stock overvalued right now?
Vaxil Bio (VXLLF) has a current Stock Based Compensation of $0.00 Mil. The current Stock Based Compensation is $0.00 Mil. Vaxil Bio's overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Vaxil Bio (VXLLF), the current Stock Based Compensation is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vaxil Bio Business Description

Other Exchanges VXL:Canada
Address 559 Briar Hill Avenue, Toronto, ON, CAN, M5N 1N1
Vaxil Bio Ltd is a biotechnology company focused on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. In recent years, the Company has been more focused on P-EsbpDOX. The Company develops ImMucin, a MUC1 SP-derived vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. It is also developing SP-based COVID-19 and tuberculosis vaccine/treatment candidates.
36GF Score

Get the complete analysis for VXLLF

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.04
Price